Celecoxib treatment alters the gene expression profile of normal colonic mucosa

Oleg K. Glebov, Luz M. Rodriguez, Patrick Lynch, Sherri Patterson, Henry T. Lynch, Kenneth Nakahara, Jean Jenkins, Janet Cliatt, Casey Jo Humbyrd, John DeNobile, Peter Soballe, Steven Gallinger, Aby Buchbinder, Gary Gordon, Ernest Hawk, Ilan R. Kirsch

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is

Original languageEnglish
Pages (from-to)1382-1391
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Celecoxib
Transcriptome
Mucous Membrane
Placebos
Hereditary Nonpolyposis Colorectal Neoplasms
Therapeutics
Cyclooxygenase 2 Inhibitors
Neoplasm Genes
Oligonucleotide Array Sequence Analysis
Multicenter Studies
Colon
Biomarkers
Clinical Trials
Technology
Safety
Gene Expression

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Celecoxib treatment alters the gene expression profile of normal colonic mucosa. / Glebov, Oleg K.; Rodriguez, Luz M.; Lynch, Patrick; Patterson, Sherri; Lynch, Henry T.; Nakahara, Kenneth; Jenkins, Jean; Cliatt, Janet; Humbyrd, Casey Jo; DeNobile, John; Soballe, Peter; Gallinger, Steven; Buchbinder, Aby; Gordon, Gary; Hawk, Ernest; Kirsch, Ilan R.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 7, 07.2006, p. 1382-1391.

Research output: Contribution to journalArticle

Glebov, OK, Rodriguez, LM, Lynch, P, Patterson, S, Lynch, HT, Nakahara, K, Jenkins, J, Cliatt, J, Humbyrd, CJ, DeNobile, J, Soballe, P, Gallinger, S, Buchbinder, A, Gordon, G, Hawk, E & Kirsch, IR 2006, 'Celecoxib treatment alters the gene expression profile of normal colonic mucosa', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 7, pp. 1382-1391. https://doi.org/10.1158/1055-9965.EPI-04-0866
Glebov, Oleg K. ; Rodriguez, Luz M. ; Lynch, Patrick ; Patterson, Sherri ; Lynch, Henry T. ; Nakahara, Kenneth ; Jenkins, Jean ; Cliatt, Janet ; Humbyrd, Casey Jo ; DeNobile, John ; Soballe, Peter ; Gallinger, Steven ; Buchbinder, Aby ; Gordon, Gary ; Hawk, Ernest ; Kirsch, Ilan R. / Celecoxib treatment alters the gene expression profile of normal colonic mucosa. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 7. pp. 1382-1391.
@article{d6a80fdf9ba245b481d2df92c0ea8d6e,
title = "Celecoxib treatment alters the gene expression profile of normal colonic mucosa",
abstract = "A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is",
author = "Glebov, {Oleg K.} and Rodriguez, {Luz M.} and Patrick Lynch and Sherri Patterson and Lynch, {Henry T.} and Kenneth Nakahara and Jean Jenkins and Janet Cliatt and Humbyrd, {Casey Jo} and John DeNobile and Peter Soballe and Steven Gallinger and Aby Buchbinder and Gary Gordon and Ernest Hawk and Kirsch, {Ilan R.}",
year = "2006",
month = "7",
doi = "10.1158/1055-9965.EPI-04-0866",
language = "English",
volume = "15",
pages = "1382--1391",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Celecoxib treatment alters the gene expression profile of normal colonic mucosa

AU - Glebov, Oleg K.

AU - Rodriguez, Luz M.

AU - Lynch, Patrick

AU - Patterson, Sherri

AU - Lynch, Henry T.

AU - Nakahara, Kenneth

AU - Jenkins, Jean

AU - Cliatt, Janet

AU - Humbyrd, Casey Jo

AU - DeNobile, John

AU - Soballe, Peter

AU - Gallinger, Steven

AU - Buchbinder, Aby

AU - Gordon, Gary

AU - Hawk, Ernest

AU - Kirsch, Ilan R.

PY - 2006/7

Y1 - 2006/7

N2 - A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is

AB - A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is

UR - http://www.scopus.com/inward/record.url?scp=33746411410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746411410&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-04-0866

DO - 10.1158/1055-9965.EPI-04-0866

M3 - Article

VL - 15

SP - 1382

EP - 1391

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -